ABSTRACT: 

IL-17 is a member of the innate immune system, it is preferentially expressed by Th2 cells, and is highly recognized in psoriasis skin lesions. The current study aims investigate the role of Interleukin-17 (IL-17) in development and severity of psoriasis (PsO). Eighty persons from both genders are included in the study, 40 of them were patients and the same number were as control. Blood samples were taken from both groups and ELISA ready kit was used to estimate the sera levels of IL-17. The current findings pointed to a significant increase (p<0.05) in the of serum IL-17 in the patients’ group in comparison with the control group (20.97 ± 12.93 vs 20.97 ± 12.93 respectively). The results also showed that there is a highly significant increase in mean levels of IL-17 (20.3 pg/ml) in patients with moderate PsO and (20.8 pg/ml) for patients with severe PsO, compared to those with mild PSO. Conclusion: It was concluded that the high levels of IL-17 in psoriasis, and it seem that this interleukin may contribute to the severity of the disease. No gender differences were seen regarding the level of IL-17.

KEYWORDS:

Interleukin-17, psoriasis, severity, skin disorders

REFERENCES :

1) Oleiwi, A. H. Some Cytokines Levels (IL-6 and IL-10) in Sera Patients with Cutaneous Leishmaniasis in Nassiriya Province. University of Thi-Qar Journal of Science, 2020, 7(2), 4-6.‏
2) Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
3) Takeshita J, Grewal S, Langan SM et al Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol, 2017; 76:393–40.
4) Lande R, Botti E, Jandus C et al The antimicrobial peptide LL37 is a T‐cell autoantigen in psoriasis. Nat Commun 2014; 5:5621.
5) Clark RA. Resident memory T cells in human health and disease. Sci Transl Med 2015; 7:269rv1.
6) Johnston A, Fritz Y, Dawes SM et al Keratinocyte overexpression of IL‐17C promotes psoriasiform skin inflammation. J Immunol 2013; 190:2252–62.
7) Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859–866.
8) Al-Fahham, A.A. Development of New LSD Formula when Unequal Observations Numbers of Observations Are. Open Journal of Statistics, 2018, 8, 258-263.https://doi.org/10.4236/ojs.2018.82016.
9) Mina, S., Jabeen, M., Singh, S., & Verma, R. Gender differences in depression and anxiety among psoriasis patients. Indian journal of dermatology, 2015, 60(2), 211.
10) Bahnan, B., Shabu, S., & Amedi, S. The pattern of psoriasis in a group of patients attending two private clinics in Erbil city. Zanco Journal of Medical Sciences, 2019, 23(3), 403-41. Hawler Medical University.
11) Kim, D. H., Li, K., Seo, S. J., Jo, S. J., Yim, H. W., Kim, C. M., Kim, K. H., Kim, D. W., Kim, M. B., Kim, J. W., Ro, Y. S., Park, Y. L., Park, C. W., Lee, S. C., & Cho, S. H. Quality of life and disease severity are correlated in patients with psoriasis. Journal of Korean medical science, 2012, 27(11), 1327–1332.
12) 12. 6. Kalmarzi, R., Ataee, P., Homagostar, Gh., Tagik, M., Ghaderi, E., & Kooti, W. Evaluation of the frequency of food allergens based on skin prick test in children in Kurdistan Province – Iran. Allergologia et Immunopathologia, 2018, 46(1), 45–57.
Chu, H., Shin, J. U., Park, C. O., Lee, H., Lee, J., & Lee, K. H. Clinical Diversity of Psoriasis: A Review of 5,000 Patients at a Single Institute. Allergy, asthma & immunology research, 2017, 9(2), 158–168.
13) Kareem, Y. A. and Al-Thwani, A. N. Evaluation of IL-17, IL-18and IL-22 as Vital indicators of Iraqi Patients with Psoriasis. Iraqi Journal of Biotechnology, 2021, 20, (1): 103-108.
14) Rautiainen, R. H., & Reynolds, S. J. Mortality and morbidity in agriculture in the United States. Journal of Agricultural Safety and Health, 2002, 8(3), 259.
15) Hadi WS, Salman RS, Al-Fahham AA, Faryad Khan MU, Kadir S, Laft MH, Saeed BQ, Kadhum WR, Jalil AT, Kadhim MM. Evaluation of IL-17 and IL-35 in patients with giardiasis in Thi-Qar province, Iraq. J Med Life. 2022 Sep;15(9):1096-1099. doi: 10.25122/jml-2021-0328..
16) Razzaq, A.; Al-Saadi, M. Ahmed M, and Naji, T. Estimation of Interlukine-IL-17A and IL-23 in Psoriasis Iraqi Patients. Journal of Science, 2015, 5 (3): 204-207.
17) Al-Janabi H. K. Cytological and Some Immunological Factors in Psoriatic Patients treated with Etanercept. PhD Thesis, 2018, College of Science, University of Baghdad.
18) Abd Alkhaliq G. Q. Immunological Study for a Sample of Iraqi Psoriatic Patients. MSc, 2020, Thesis, College of Science, University of Baghdad.
19) Nygaard, U., Hvid, M., Johansen, C., Buchner, M., Fölster-Holst, R., Deleuran, M., & Vestergaard, C. TSLP, IL-17, IL-33, and sST2 are new biomarkers in endophenotypic profiling of adult and childhood psoriasis. Journal of the European Academy of Dermatology and Venereology: JEADV, 2016, 30(11), 1930–1938.
20) Golden, J. McCormick, T. and Ward, L. IL-17 in psoriasis, Implications for therapy and cardiovascular co-morbidities. Cytokine, 2013, 62(2), 195-20.
21) Szegedi, K., Kremer, A. E., Kezic, S., Teunissen, M. B., Bos, J. D., Luiten, R. M., Res, P. C., & Middelkamp-Hup, M. A. Increased frequencies of IL-17-producing T cells are found in chronic psoriasis skin. Experimental dermatology, 2012, 21(6), 431–436.